271 related articles for article (PubMed ID: 16062075)
1. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Mishra G; Butler J; Ho C; Melin S; Case LD; Ennever PR; Magrinat GC; Bearden JD; Minotto DC; Howerton R; Levine E; Blackstock AW
Am J Clin Oncol; 2005 Aug; 28(4):345-50. PubMed ID: 16062075
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.
Blackstock AW; Melin SA; Butler JM; Patton S; Pineau B; Albertson D; Howerton R; Levine E
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):25-8. PubMed ID: 12109802
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
[TBL] [Abstract][Full Text] [Related]
4. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
[TBL] [Abstract][Full Text] [Related]
5. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
6. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
Crane CH; Varadhachary GR; Yordy JS; Staerkel GA; Javle MM; Safran H; Haque W; Hobbs BD; Krishnan S; Fleming JB; Das P; Lee JE; Abbruzzese JL; Wolff RA
J Clin Oncol; 2011 Aug; 29(22):3037-43. PubMed ID: 21709185
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
Kurt E; Kurt M; Kanat O; Cetintas SK; Aygun S; Palazoglu T; Ozkan L; Evrensel T; Kaya E; Manavoglu O
Tumori; 2006; 92(6):481-6. PubMed ID: 17260487
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
[TBL] [Abstract][Full Text] [Related]
13. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Stathopoulos GP; Rigatos SK; Dimopoulos MA; Giannakakis T; Foutzilas G; Kouroussis C; Janninis D; Aravantinos G; Androulakis N; Agelaki S; Stathopoulos JG; Georgoulias V;
Ann Oncol; 2003 Mar; 14(3):388-94. PubMed ID: 12598343
[TBL] [Abstract][Full Text] [Related]
15. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C
J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
Haddock MG; Swaminathan R; Foster NR; Hauge MD; Martenson JA; Camoriano JK; Stella PJ; Tenglin RC; Schaefer PL; Moore DF; Alberts SR
J Clin Oncol; 2007 Jun; 25(18):2567-72. PubMed ID: 17577035
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
Sun W; Hewitt MR; Theobald MR; Hershock D; Haller DG
Cancer; 2007 Dec; 110(12):2768-74. PubMed ID: 17932893
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
Chaudhary UB; Verma N; Keane T; Gudena V
Am J Clin Oncol; 2014 Apr; 37(2):188-93. PubMed ID: 23241501
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]